Gemphire Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Investors
  • 2

Gemphire Therapeutics General Information

Description

Developer of novel therapies designed to treat life threatening cardiovascular or metabolic and orphan diseases. The company is engaged in developing and commercializing therapies for patients with cardiometablic disorders including dyslipidemia and nash.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 17199 North Laurel Park Drive
  • Suite 401
  • Livonia, MI 48152
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 17199 North Laurel Park Drive
  • Suite 401
  • Livonia, MI 48152
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gemphire Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 30-Dec-2019 Completed Generating Revenue
6. Secondary Transaction - Private Completed Generating Revenue
5. PIPE 04-Sep-2017 Completed Generating Revenue
4. PIPE 10-Mar-2017 Completed Generating Revenue
3. IPO 04-Aug-2016 Completed Generating Revenue
2. Early Stage VC (Series A) 09-Mar-2016 $10.6M $10.6M Completed Generating Revenue
1. Angel (individual) Completed Generating Revenue
To view Gemphire Therapeutics’s complete valuation and funding history, request access »

Gemphire Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Gemphire Therapeutics’s complete cap table history, request access »

Gemphire Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amherst Fund Venture Capital Minority
Biobrit Venture Capital Minority
Biosciences Research and Commercialization Center Venture Capital Minority
BlueWater Angels Angel Group Minority
Capital Midwest Fund Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Gemphire Therapeutics Acquisitions (1)

Gemphire Therapeutics’s most recent deal was a Reverse Merger with MetaVia (Biotechnology). The deal was made on 30-Jan-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
MetaVia (Biotechnology) 30-Jan-2020 Reverse Merger Biotechnology
To view Gemphire Therapeutics’s complete acquisitions history, request access »

Gemphire Therapeutics FAQs

  • When was Gemphire Therapeutics founded?

    Gemphire Therapeutics was founded in 2008.

  • Where is Gemphire Therapeutics headquartered?

    Gemphire Therapeutics is headquartered in Livonia, MI.

  • What industry is Gemphire Therapeutics in?

    Gemphire Therapeutics’s primary industry is Drug Discovery.

  • Is Gemphire Therapeutics a private or public company?

    Gemphire Therapeutics is a Private company.

  • What is Gemphire Therapeutics’s current revenue?

    The current revenue for Gemphire Therapeutics is .

  • How much funding has Gemphire Therapeutics raised over time?

    Gemphire Therapeutics has raised $103M.

  • Who are Gemphire Therapeutics’s investors?

    Amherst Fund, Biobrit, Biosciences Research and Commercialization Center, BlueWater Angels, and Capital Midwest Fund are 5 of 11 investors who have invested in Gemphire Therapeutics.

  • When was Gemphire Therapeutics acquired?

    Gemphire Therapeutics was acquired on 30-Dec-2019.

  • Who acquired Gemphire Therapeutics?

    Gemphire Therapeutics was acquired by MetaVia (Biotechnology).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »